ScandiDos AB (SDOS) - Net Assets
Based on the latest financial reports, ScandiDos AB (SDOS) has net assets worth Skr41.66 Million SEK (≈ $4.48 Million USD) as of April 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr65.97 Million ≈ $7.10 Million USD) and total liabilities (Skr24.31 Million ≈ $2.62 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore balance sheet size of ScandiDos AB for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr41.66 Million |
| % of Total Assets | 63.15% |
| Annual Growth Rate | 8.62% |
| 5-Year Change | 12.0% |
| 10-Year Change | -5.32% |
| Growth Volatility | 77.62 |
ScandiDos AB - Net Assets Trend (2011–2026)
This chart illustrates how ScandiDos AB's net assets have evolved over time, based on quarterly financial data. Check SDOS goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for ScandiDos AB (2011–2026)
The table below shows the annual net assets of ScandiDos AB from 2011 to 2026. For live valuation and market cap data, see market cap of ScandiDos AB.
| Year | Net Assets | Change |
|---|---|---|
| 2026-04-30 | Skr41.66 Million ≈ $4.48 Million |
-7.38% |
| 2025-04-30 | Skr44.98 Million ≈ $4.84 Million |
+1.56% |
| 2024-04-30 | Skr44.29 Million ≈ $4.77 Million |
+6.32% |
| 2023-04-30 | Skr41.65 Million ≈ $4.48 Million |
+11.98% |
| 2022-04-30 | Skr37.20 Million ≈ $4.00 Million |
-17.67% |
| 2021-04-30 | Skr45.18 Million ≈ $4.86 Million |
-2.33% |
| 2020-04-30 | Skr46.26 Million ≈ $4.98 Million |
+61.64% |
| 2019-04-30 | Skr28.62 Million ≈ $3.08 Million |
-38.56% |
| 2018-04-30 | Skr46.58 Million ≈ $5.01 Million |
+5.85% |
| 2017-04-30 | Skr44.00 Million ≈ $4.74 Million |
+37.51% |
| 2016-04-30 | Skr32.00 Million ≈ $3.44 Million |
+26.26% |
| 2015-04-30 | Skr25.34 Million ≈ $2.73 Million |
-37.40% |
| 2014-04-30 | Skr40.48 Million ≈ $4.36 Million |
+296.54% |
| 2013-04-30 | Skr10.21 Million ≈ $1.10 Million |
-17.11% |
| 2012-04-30 | Skr12.32 Million ≈ $1.33 Million |
+2.23% |
| 2011-04-30 | Skr12.05 Million ≈ $1.30 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ScandiDos AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52828.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr2.85 Million | 6.84% |
| Other Components | Skr208.07 Million | 499.42% |
| Total Equity | Skr41.66 Million | 100.00% |
ScandiDos AB Competitors by Market Cap
The table below lists competitors of ScandiDos AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Foresight Autonomous Holdings Ltd ADR
NASDAQ:FRSX
|
$5.09 Million |
|
Archies Limited
NSE:ARCHIES
|
$5.10 Million |
|
Liminatus Pharma, Inc. Class A Common Stock
NASDAQ:LIMN
|
$5.10 Million |
|
BACTECH ENVIRONMENT.CORP.
F:0BT1
|
$5.11 Million |
|
Nala Digital Commerce Ltd
TA:SEFA
|
$5.08 Million |
|
Ahlada Engineers Limited
NSE:AHLADA
|
$5.08 Million |
|
KNM Group Bhd
KLSE:7164
|
$5.08 Million |
|
Megapower Makmur TBK PT
JK:MPOW
|
$5.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ScandiDos AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 44,980,000 to 41,662,000, a change of -3,318,000 (-7.4%).
- Net loss of 3,435,000 reduced equity.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-3.44 Million | -8.24% |
| Other Changes | Skr117.00K | +0.28% |
| Total Change | Skr- | -7.38% |
Book Value vs Market Value Analysis
This analysis compares ScandiDos AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.15x to 1.14x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-04-30 | Skr5.57 | Skr0.83 | x |
| 2012-04-30 | Skr5.69 | Skr0.83 | x |
| 2013-04-30 | Skr4.72 | Skr0.83 | x |
| 2014-04-30 | Skr2.78 | Skr0.83 | x |
| 2015-04-30 | Skr1.86 | Skr0.83 | x |
| 2016-04-30 | Skr1.68 | Skr0.83 | x |
| 2017-04-30 | Skr1.66 | Skr0.83 | x |
| 2018-04-30 | Skr1.54 | Skr0.83 | x |
| 2019-04-30 | Skr0.99 | Skr0.83 | x |
| 2020-04-30 | Skr1.12 | Skr0.83 | x |
| 2021-04-30 | Skr1.09 | Skr0.83 | x |
| 2022-04-30 | Skr0.90 | Skr0.83 | x |
| 2023-04-30 | Skr0.91 | Skr0.83 | x |
| 2024-04-30 | Skr0.97 | Skr0.83 | x |
| 2025-04-30 | Skr0.99 | Skr0.83 | x |
| 2026-04-30 | Skr0.73 | Skr0.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ScandiDos AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.34%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 1.58x
- Recent ROE (-8.24%) is above the historical average (-24.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 2.66% | 1.11% | 1.49x | 1.62x | Skr-883.80K |
| 2012 | 1.84% | 0.63% | 1.47x | 1.98x | Skr-1.00 Million |
| 2013 | -20.50% | -5.25% | 1.35x | 2.88x | Skr-3.11 Million |
| 2014 | -10.37% | -10.85% | 0.72x | 1.33x | Skr-8.25 Million |
| 2015 | -57.94% | -44.60% | 0.76x | 1.71x | Skr-17.22 Million |
| 2016 | -44.51% | -42.42% | 0.58x | 1.80x | Skr-17.44 Million |
| 2017 | -29.90% | -27.75% | 0.75x | 1.44x | Skr-17.56 Million |
| 2018 | -24.83% | -22.87% | 0.76x | 1.42x | Skr-16.22 Million |
| 2019 | -62.06% | -36.38% | 0.71x | 2.42x | Skr-20.62 Million |
| 2020 | -28.39% | -22.93% | 0.81x | 1.53x | Skr-17.76 Million |
| 2021 | -3.10% | -2.33% | 0.78x | 1.71x | Skr-5.92 Million |
| 2022 | -19.73% | -12.72% | 0.87x | 1.78x | Skr-11.06 Million |
| 2023 | -21.89% | -14.82% | 0.85x | 1.74x | Skr-13.28 Million |
| 2024 | -33.07% | -24.24% | 0.74x | 1.84x | Skr-19.08 Million |
| 2025 | -32.56% | -24.24% | 0.82x | 1.63x | Skr-19.14 Million |
| 2026 | -8.24% | -6.34% | 0.82x | 1.58x | Skr-7.60 Million |
Industry Comparison
This section compares ScandiDos AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $800,632,547
- Average return on equity (ROE) among peers: -104.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ScandiDos AB (SDOS) | Skr41.66 Million | 2.66% | 0.58x | $5.09 Million |
| Acarix A/S (ACARIX) | $128.94 Million | -23.09% | 0.04x | $31.27 Million |
| Arcoma AB (ARCOMA) | $49.92 Million | -12.92% | 0.69x | $12.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $370.82 Million | -4.03% | 0.58x | $55.79 Million |
| BICO Group AB (BICO) | $6.93 Billion | -12.06% | 0.47x | $110.76 Million |
| Boule Diagnostics AB (BOUL) | $295.74 Million | 7.87% | 0.93x | $15.88 Million |
| CellaVision AB (CEVI) | $151.30 Million | 20.80% | 0.34x | $379.89 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $7.00 Million | -619.91% | 4.53x | $6.27 Million |
| Chordate Medical Holding AB (CMH) | $11.26 Million | -236.91% | 0.88x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $48.12 Million | -20.45% | 0.41x | $123.07 Million |
| Duearity AB (DEAR) | $11.04 Million | -140.58% | 0.46x | $331.97K |
About ScandiDos AB
ScandiDos AB (publ), together with its subsidiaries, provides measurement phantoms and software solutions for the quality assurance and validation of dynamic and modulated treatments adopted in clinics in the United States, Europe, Asia, and internationally. The company offers Delta4 products comprising Delta4 Phantom+, Delta4Phantom+MR, Delta4 HexaMotion, Delta4Insight, Delta4DVH Anatomy, Delta4… Read more